VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LGVN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LGVNLongeveron Inc.
$1.92$6M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksLGVNCash Flow

Longeveron Inc. (LGVN) Cash Flow Statement

8Y historyFree accessUpdated daily

Persistent free cash flow deficits, often exceeding $4M per quarter, underscore a reliance on external capital as the OCF/NI ratio frequently tracks between 0.70 and 0.97.

Income StatementBalance SheetCash FlowRatios

LGVN Cash Flow Statement

Annual statement

LGVN Cash Flow Statement

Longeveron Inc. (LGVN) cash flow statement — 8-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Cash from Operations-18.01M-18.64M-13.87M-19M-13.97M-9.64M-2.36M-2.39M-5.18M
Operating CF Margin %--1555.05%-579.77%-2680.11%-1143.13%-737.83%-42%-42.47%-242.57%
Operating CF Growth %-60.38%-34.45%27.02%-36.03%-44.97%-307.63%1.13%53.83%-
Net Income-22.39M-22.7M-15.97M-21.41M-18.84M-17.05M-3.72M-2.96M-6.34M
Depreciation & Amortization977K1.23M958K946K893K914K785K768.84K745.77K
Stock-Based Compensation1.65M1.68M2.33M2.03M2.17M7.74M83K136.85K423.87K
Deferred Taxes000000000
Other Non-Cash Items346K97K60K-603K1.57M-155K270-120.13K1.9M
Working Capital Changes1.41M1.06M-1.24M36K238K-1.09M488.63K-216.48K-11.22K
Change in Receivables-12K-20K27K107K-164K366K30.81K-451.46K24.88K
Change in Inventory00000-366K-30.81K00
Change in Payables882K325K-540K01.11M-945K130.94K0-13.09K
Cash from Investing-253K-595K-640K8.19M-677K-10.7M-261.5K-125.05K-211.68K
Capital Expenditures-252K-595K-992K-301K-856K-1.31M-261.5K-37.57K-211.68K
CapEx % of Revenue21.63%49.62%41.47%42.45%70.05%100.31%4.65%0.67%9.92%
Acquisitions0000085K000
Investments---------
Other Investing-1K008.49M0-9.39M0-87.47K-115.72K
Cash from Financing16.26M4.67M28.79M5.26M-509K45.17M1.58M350K1.35M
Debt Issued (Net)00000-188K488K00
Equity Issued (Net)30.35M4.98M12.87M-174K2K45.81M1.1M00
Dividends Paid00-8.65M000000
Share Repurchases000-174K00000
Other Financing-14.09M-311K24.57M5.44M-511K-451K-12.67K350K1.35M
Net Change in Cash-2M-14.57M14.28M-5.55M-15.15M24.84M-1.05M-2.17M-4.04M
Free Cash Flow-18.24M-18.89M-14.86M-19.3M-14.82M-10.95M-2.63M-2.43M-5.39M
FCF Margin %-1565.58%-1575.48%-621.24%-2722.57%-1213.18%-838.13%-46.64%-43.14%-252.49%
FCF Growth %-5.64%-27.12%23.02%-30.21%-35.44%-316.93%-8.11%54.95%-
FCF per Share-5.68-10.75-9.98-88.81-70.70-57.87-15.57-15.16-33.89
FCF Conversion (FCF/Net Income)0.81x0.82x0.87x0.89x0.74x0.57x0.64x0.64x0.82x
Interest Paid000000000
Taxes Paid000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Imminent liquidity and dilution

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Quality Obscured by Burn

Based on the provided financial data, Longeveron's operating cash flow consistently tracks net losses, with an OCF/NI ratio often hovering near 0.70 to 0.97, suggesting that the company's reported net income is largely a reflection of cash-based operational expenditures rather than non-cash accounting accruals.

The tight correlation between net income and operating cash flow indicates that the company lacks significant non-cash charges that would otherwise bridge the gap between accounting losses and cash reality. This suggests that the firm's financial statements are a direct proxy for its cash burn rate, leaving little room for earnings quality adjustments.

Persistent FCF Deficit Limits Runway

As reported in quarterly filings, Longeveron's free cash flow remains consistently negative, with quarterly outflows frequently exceeding $4M, a trend that highlights the company's inability to generate self-sustaining capital while advancing its clinical pipeline through high-cost research and development phases.

The persistent negative FCF margins, which have reached as low as -67.6%, underscore the structural challenge of funding clinical trials without a commercial revenue base. Investors should monitor whether the company can stabilize these outflows, as the current trajectory necessitates frequent external capital injections.

Volatile Working Capital Impacts Liquidity

According to the cash flow statements, working capital changes have been highly erratic, swinging from a $1.1M inflow in 2025Q3 to a $603K outflow in 2025Q4, which suggests that the timing of grant receipts and vendor payments creates significant, unpredictable fluctuations in quarterly cash availability.

This volatility in working capital appears to be a byproduct of the company's reliance on milestone-based funding and clinical trial service contracts. Such instability complicates cash flow forecasting and may exacerbate liquidity pressures during periods where grant inflows do not align with operational payment obligations.

SBC and Capitalized Costs Masking

Based on the provided data, stock-based compensation (SBC) has periodically reached as high as $2.3M in a single quarter, which serves to obscure the true economic cost of operations by shifting expenses from cash-based compensation to non-cash equity dilution for shareholders.

While SBC is a standard tool for talent retention in biotech, its magnitude relative to the company's total cash burn warrants close scrutiny. This practice effectively shifts the burden of operational funding from the income statement to the equity base, potentially diluting existing investors to cover the cost of human capital.

LGVN — Frequently Asked Questions

Quick answers to the most common questions about buying LGVN stock.

How much cash does Longeveron Inc. (LGVN) generate from operations?

Longeveron Inc. (LGVN) generated $-18.6M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Longeveron Inc.'s free cash flow?

Longeveron Inc. (LGVN) reported negative free cash flow of $18.9M in 2025, indicating capital requirements exceeded cash from operations.

What is Longeveron Inc.'s capital expenditure (CapEx)?

Longeveron Inc. (LGVN) spent $0.6M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.